AAPL332.59+10.93 (+3.40%) ▲|ABBV258.25+1.33 (+0.52%) ▲|ABT103.18+2.43 (+2.41%) ▲|ACN146.05+7.31 (+5.27%) ▲|ADBE224.79+12.62 (+5.95%) ▲|AMAT540.83-21.97 (-3.90%) ▼|AMD527.92-11.78 (-2.18%) ▼|AMGN375.80+4.30 (+1.16%) ▲|AMT167.46+2.81 (+1.71%) ▲|AMZN232.44-1.22 (-0.52%) ▼|AVGO381.50-10.97 (-2.80%) ▼|AXP323.60-17.24 (-5.06%) ▼|BA211.39+2.16 (+1.03%) ▲|BAC61.97+0.69 (+1.12%) ▲|BKNG178.48+5.65 (+3.27%) ▲|BLK1,052.74+15.58 (+1.50%) ▲|BMY62.01+0.50 (+0.81%) ▲|BNY159.03-1.08 (-0.67%) ▼|BRK-B492.14+1.29 (+0.26%) ▲|C132.18+0.30 (+0.22%) ▲|CAT888.77-5.77 (-0.65%) ▼|CL90.48+0.40 (+0.44%) ▲|CMCSA22.43+0.51 (+2.30%) ▲|COF202.15+2.19 (+1.10%) ▲|COP120.36+0.16 (+0.13%) ▲|COST932.51+6.45 (+0.70%) ▲|CRM163.30+6.37 (+4.06%) ▲|CSCO113.45+0.69 (+0.61%) ▲|CVS107.35+0.46 (+0.43%) ▲|CVX195.15+0.73 (+0.37%) ▲|DE622.97+12.95 (+2.12%) ▲|DHR190.76-1.75 (-0.91%) ▼|DIS95.47+2.64 (+2.84%) ▲|DUK129.96+0.70 (+0.54%) ▲|EMR148.03+3.13 (+2.16%) ▲|FDX317.67+2.05 (+0.65%) ▲|GD385.74+3.95 (+1.03%) ▲|GE353.87+4.87 (+1.40%) ▲|GEV1,008.63-22.57 (-2.19%) ▼|GILD129.76-1.10 (-0.84%) ▼|GM82.24+1.57 (+1.94%) ▲|GOOG320.16+1.82 (+0.57%) ▲|GOOGL320.52+2.83 (+0.89%) ▲|GS1,065.11-9.61 (-0.89%) ▼|HD331.23+6.52 (+2.01%) ▲|HON241.05-5.22 (-2.12%) ▼|IBM215.63+8.98 (+4.34%) ▲|INTC94.57-5.67 (-5.65%) ▼|INTU293.02+11.49 (+4.08%) ▲|ISRG338.15+6.13 (+1.85%) ▲|JNJ262.81+3.54 (+1.37%) ▲|JPM352.78+2.88 (+0.82%) ▲|KO82.12+0.95 (+1.17%) ▲|LIN512.25+5.93 (+1.17%) ▲|LLY1,192.60+6.73 (+0.57%) ▲|LMT581.87+13.28 (+2.33%) ▲|LOW206.37+4.45 (+2.20%) ▲|LRCX308.15-11.63 (-3.64%) ▼|MA535.59+5.30 (+1.00%) ▲|MCD264.80+2.00 (+0.76%) ▲|MDLZ60.43+0.38 (+0.63%) ▲|MDT83.17+1.16 (+1.41%) ▲|META601.64-4.46 (-0.74%) ▼|MMM170.74+1.15 (+0.68%) ▲|MO73.02+0.94 (+1.30%) ▲|MRK131.06+0.58 (+0.44%) ▲|MS214.83-0.35 (-0.16%) ▼|MSFT384.21+2.63 (+0.69%) ▲|MU921.13-69.08 (-6.98%) ▼|NEE89.17-0.63 (-0.70%) ▼|NFLX70.21+1.32 (+1.91%) ▲|NKE41.82+0.83 (+2.01%) ▲|NOW98.04+6.10 (+6.63%) ▲|NVDA208.57-0.19 (-0.09%) ▼|ORCL116.98-3.07 (-2.55%) ▼|PEP136.67+1.72 (+1.27%) ▲|PFE24.57-0.02 (-0.06%) ▼|PG146.79+0.91 (+0.62%) ▲|PLTR123.90+0.53 (+0.43%) ▲|PM194.43+3.31 (+1.73%) ▲|QCOM167.52-3.59 (-2.10%) ▼|RTX212.90+3.74 (+1.79%) ▲|SBUX103.83+0.62 (+0.60%) ▲|SCHW101.44-0.17 (-0.17%) ▼|SO97.12+0.52 (+0.54%) ▲|SPG228.87+3.67 (+1.63%) ▲|T23.97+1.01 (+4.39%) ▲|TMO562.88-9.44 (-1.65%) ▼|TMUS180.36+9.94 (+5.83%) ▲|TSLA308.00-11.69 (-3.66%) ▼|TXN280.99-4.01 (-1.41%) ▼|UBER69.00+0.09 (+0.13%) ▲|UNH419.92-3.64 (-0.86%) ▼|UNP307.54+3.21 (+1.05%) ▲|UPS114.86+0.76 (+0.67%) ▲|USB63.79+0.46 (+0.73%) ▲|V353.97+2.37 (+0.67%) ▲|VZ45.73+1.91 (+4.35%) ▲|WFC86.45+0.26 (+0.30%) ▲|WMT109.31+0.91 (+0.84%) ▲|XOM156.97+0.08 (+0.05%) ▲|AAPL332.59+10.93 (+3.40%) ▲|ABBV258.25+1.33 (+0.52%) ▲|ABT103.18+2.43 (+2.41%) ▲|ACN146.05+7.31 (+5.27%) ▲|ADBE224.79+12.62 (+5.95%) ▲|AMAT540.83-21.97 (-3.90%) ▼|AMD527.92-11.78 (-2.18%) ▼|AMGN375.80+4.30 (+1.16%) ▲|AMT167.46+2.81 (+1.71%) ▲|AMZN232.44-1.22 (-0.52%) ▼|AVGO381.50-10.97 (-2.80%) ▼|AXP323.60-17.24 (-5.06%) ▼|BA211.39+2.16 (+1.03%) ▲|BAC61.97+0.69 (+1.12%) ▲|BKNG178.48+5.65 (+3.27%) ▲|BLK1,052.74+15.58 (+1.50%) ▲|BMY62.01+0.50 (+0.81%) ▲|BNY159.03-1.08 (-0.67%) ▼|BRK-B492.14+1.29 (+0.26%) ▲|C132.18+0.30 (+0.22%) ▲|CAT888.77-5.77 (-0.65%) ▼|CL90.48+0.40 (+0.44%) ▲|CMCSA22.43+0.51 (+2.30%) ▲|COF202.15+2.19 (+1.10%) ▲|COP120.36+0.16 (+0.13%) ▲|COST932.51+6.45 (+0.70%) ▲|CRM163.30+6.37 (+4.06%) ▲|CSCO113.45+0.69 (+0.61%) ▲|CVS107.35+0.46 (+0.43%) ▲|CVX195.15+0.73 (+0.37%) ▲|DE622.97+12.95 (+2.12%) ▲|DHR190.76-1.75 (-0.91%) ▼|DIS95.47+2.64 (+2.84%) ▲|DUK129.96+0.70 (+0.54%) ▲|EMR148.03+3.13 (+2.16%) ▲|FDX317.67+2.05 (+0.65%) ▲|GD385.74+3.95 (+1.03%) ▲|GE353.87+4.87 (+1.40%) ▲|GEV1,008.63-22.57 (-2.19%) ▼|GILD129.76-1.10 (-0.84%) ▼|GM82.24+1.57 (+1.94%) ▲|GOOG320.16+1.82 (+0.57%) ▲|GOOGL320.52+2.83 (+0.89%) ▲|GS1,065.11-9.61 (-0.89%) ▼|HD331.23+6.52 (+2.01%) ▲|HON241.05-5.22 (-2.12%) ▼|IBM215.63+8.98 (+4.34%) ▲|INTC94.57-5.67 (-5.65%) ▼|INTU293.02+11.49 (+4.08%) ▲|ISRG338.15+6.13 (+1.85%) ▲|JNJ262.81+3.54 (+1.37%) ▲|JPM352.78+2.88 (+0.82%) ▲|KO82.12+0.95 (+1.17%) ▲|LIN512.25+5.93 (+1.17%) ▲|LLY1,192.60+6.73 (+0.57%) ▲|LMT581.87+13.28 (+2.33%) ▲|LOW206.37+4.45 (+2.20%) ▲|LRCX308.15-11.63 (-3.64%) ▼|MA535.59+5.30 (+1.00%) ▲|MCD264.80+2.00 (+0.76%) ▲|MDLZ60.43+0.38 (+0.63%) ▲|MDT83.17+1.16 (+1.41%) ▲|META601.64-4.46 (-0.74%) ▼|MMM170.74+1.15 (+0.68%) ▲|MO73.02+0.94 (+1.30%) ▲|MRK131.06+0.58 (+0.44%) ▲|MS214.83-0.35 (-0.16%) ▼|MSFT384.21+2.63 (+0.69%) ▲|MU921.13-69.08 (-6.98%) ▼|NEE89.17-0.63 (-0.70%) ▼|NFLX70.21+1.32 (+1.91%) ▲|NKE41.82+0.83 (+2.01%) ▲|NOW98.04+6.10 (+6.63%) ▲|NVDA208.57-0.19 (-0.09%) ▼|ORCL116.98-3.07 (-2.55%) ▼|PEP136.67+1.72 (+1.27%) ▲|PFE24.57-0.02 (-0.06%) ▼|PG146.79+0.91 (+0.62%) ▲|PLTR123.90+0.53 (+0.43%) ▲|PM194.43+3.31 (+1.73%) ▲|QCOM167.52-3.59 (-2.10%) ▼|RTX212.90+3.74 (+1.79%) ▲|SBUX103.83+0.62 (+0.60%) ▲|SCHW101.44-0.17 (-0.17%) ▼|SO97.12+0.52 (+0.54%) ▲|SPG228.87+3.67 (+1.63%) ▲|T23.97+1.01 (+4.39%) ▲|TMO562.88-9.44 (-1.65%) ▼|TMUS180.36+9.94 (+5.83%) ▲|TSLA308.00-11.69 (-3.66%) ▼|TXN280.99-4.01 (-1.41%) ▼|UBER69.00+0.09 (+0.13%) ▲|UNH419.92-3.64 (-0.86%) ▼|UNP307.54+3.21 (+1.05%) ▲|UPS114.86+0.76 (+0.67%) ▲|USB63.79+0.46 (+0.73%) ▲|V353.97+2.37 (+0.67%) ▲|VZ45.73+1.91 (+4.35%) ▲|WFC86.45+0.26 (+0.30%) ▲|WMT109.31+0.91 (+0.84%) ▲|XOM156.97+0.08 (+0.05%) ▲|
27.6 C
New York
Friday, July 24, 2026

Tag: medicines

newssourceFORcompanyinformationcontent1releasesmarket

Capricor to Present Positive Five-Year HOPE-2 OLE Data and HOPE-3 Phase 3 Results for Deramiocel in Duchenne Muscular Dystrophy at PPMD 2026 Annual Conference

SAN DIEGO, June 26, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announced positive five-year data from its ongoing HOPE-2 Open-Label Extension (OLE) study of Deramiocel, the Company’s lead cell therapy candidate for Duchenne Muscular Dystrophy (DMD). The data will be presented at the Parent Project Muscular Dystrophy (PPMD) 2026 Annual Conference, taking place June 25-27, 2026, in Orlando, Florida, alongside previously reported results from the Company’s HOPE-3 Phase 3 trial.

Lilly’s Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with chronic lymphocytic leukemia (CLL) across all lines of therapy

The positive opinion is based on results from the Phase 3 BRUIN CLL-313 and BRUIN CLL-314 trials, previously presented at the 2025 American Society...

Complex Small Molecules Are Changing Drug R&D

WuXi AppTec details how structural complexity in protein degraders, covalent agents, and kinase programs is reshaping what integrated CRDMOs must deliver.

Idorsia confirms successful closing of Pharmakon loan agreement and full repayment of New Money Facility

Allschwil, Switzerland – June 26, 2026
Idorsia Ltd (SIX: IDIA), a commercial-stage biopharmaceutical company with a portfolio of first- or best-in-class assets, today confirmed the successful closing of its previously announced senior secured term loan agreement of up to CHF 250 million with investment funds managed by Pharmakon Advisors, LP.

Everest Medicines Announces China NMPA Acceptance of the Biologics License Application for LEROCHOL® in Adults with Hypercholesterolemia

SHANGHAI, June 26, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing...

Eikon Therapeutics to Join the Russell 3000® Index

Addition reflects Eikon's progress as a publicly traded company and increasing visibility within the investment community 
Addition reflects Eikon's progress as a publicly traded company and increasing visibility within the investment community

Chiesi Group and Arbor Biotechnologies Announce ABO-101 Granted Orphan Drug Designation by European Commission for Primary Hyperoxaluria

 ABO-101 is an investigational gene editing therapy designed to address the underlying disease biology of PH1 by reducing hepatic oxalate production

EMBARC Announces Its Intention to Collaborate with Insmed on Landmark Interventional Study Evaluating Disease Modification Potential of Brensocatib in Bronchiectasis

Hannover, Germany, June 25, 2026 (GLOBE NEWSWIRE) -- EMBARC Announces Its Intention to Collaborate with Insmed on Landmark Interventional Study Evaluating Disease Modification Potential of Brensocatib in Bronchiectasis
—Long-Term, Open-Label Study to Enroll Approximately 3,000 Patients Across Europe—

Rare Neurological Disease Treatment Market to Reach USD 43.7 Billion by 2036 as Orphan Drug Approvals and Genetic Diagnostics Expand Specialist Care | Future...

NEWARK, Del., June 25, 2026 /PRNewswire/ -- According to a recent study by Future Market Insights (FMI), the global Rare Neurological Disease Treatment Market...

Rare Neurological Disease Treatment Market to Reach USD 43.7 Billion by 2036 as Orphan Drug Approvals and Genetic Diagnostics Expand Specialist Care | Future...

NEWARK, Del., June 25, 2026 /PRNewswire/ -- According to a recent study by Future Market Insights (FMI), the global Rare Neurological Disease Treatment Market...

Press Release: Sanofi Foundation opens new chapter centered on future generations

Sanofi Foundation opens new chapter centered on future generations

Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

DALLAS, June 24, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced the pricing of an underwritten public offering of 32,500,001 shares of its common stock at a price to the public of $6.00 per share and, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase 833,333 shares of its common stock at an offering price of $5.999 per pre-funded warrant, in each case before underwriting discounts and commissions. All of the securities are being offered by Taysha. In addition, Taysha has granted the underwriters a 30-day option to purchase up to an additional 5,000,000 shares of common stock at the public offering price, less underwriting discounts and commissions. The gross proceeds from the offering to Taysha are expected to be approximately $200.0 million, before deducting underwriting discounts and commissions and other offering expenses, excluding any exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on or about June 26, 2026, subject to customary closing conditions.

Cold Chain Packaging Market Size to Reach USD 93.1 Billion by 2033, Driven by Biopharmaceutical Expansion, E-commerce Growth, and Rising Demand for Temperature-Sensitive Logistics

Global market projected to grow at a CAGR of 13.5% from 2026 to 2033 as pharmaceutical, food, and healthcare industries increasingly rely on advanced...

Mesoblast Draws US$50 Million from Five-Year Non-Dilutive Facility

Optimized capital structure, retiring short-term maturing debt

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsMedicines

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers